04:13 AM EDT, 10/30/2024 (MT Newswires) -- EyePoint Pharmaceuticals ( EYPT ) said late Tuesday it priced a public offering of about 12.7 million shares at $11 apiece for gross proceeds of about $140 million, up from the initial proposed size of $100 million.

Underwriters have been granted a 30-day option to purchase up to about 1.9 million additional shares.

The offering, expected to close around Thursday, will fund the clinical development of Duravyu for wet age-related macular degeneration and diabetic macular edema, support early-stage pipeline initiatives and cover general corporate expenses.

Price: 11.53, Change: -0.01, Percent Change: -0.09